Effects of green tea on insulin sensitivity, lipid profile and expression of PPAR α and PPAR γ and their target genes in obese dogs

Samuel Serisier^{1,2}, Veronique Leray², Wilfried Poudroux^{1,2}, Thierry Magot¹, Khadija Ouguerram¹ and Patrick Nguyen²*

¹INSERM U539, University Hospital, Nantes, France ²Nutrition and Endocrinology Unit, National Veterinary School of Nantes, France

(Received 16 April 2007 - Revised 29 September 2007 - Accepted 3 October 2007 - First published online 6 December 2007)

As in man, canine obesity is associated with insulin resistance, dyslipidaemia and other chronic diseases. This study was designed to examine the effects of a nutritional supplement (green tea) on insulin sensitivity and plasma lipid concentrations in an obese insulin-resistant dog model. We also determined mRNA expression of two transcription factors, PPAR γ and PPAR α , and some of their target genes, including GLUT4, lipoprotein lipase (LPL) and adiponectin. Obese dogs were divided into two groups: a green tea group (*n* 6); a control group (*n* 4). Dogs in the green tea group were given green tea extract (80 mg/kg per d) orally, just before their single daily meal, for 12 weeks. Insulin sensitivity (using a euglycaemic – hyperinsulinaemic clamp) and concentrations of plasma TAG, total cholesterol and NEFA were assessed in each group. Gene expression was measured in visceral and subcutaneous adipose tissues and in liver and skeletal muscle, by real-time PCR. At 12 weeks in the green tea group, mean insulin sensitivity index was 60 (SEM 11) % higher (*P*<0.05) and TAG concentration 50 (SEM 10) % lower (*P*<0.001), than baseline. PPAR γ , GLUT4, LPL and adiponectin expression were significantly higher in both adipose tissues, whilst PPAR α and LPL expression were significantly higher in skeletal muscle, compared with baseline. These findings show that nutritional doses of green tea extract may improve insulin sensitivity and lipid profile and alter the expression of genes involved in glucose and lipid homeostasis.

Obese dogs: Green tea: Catechins: Insulin resistance: Dyslipidaemia: PPAR

There is abundant evidence that, worldwide, obesity and type 2 diabetes have dramatically increased over recent decades⁽¹⁾. Obesity is closely associated with insulin resistance and other chronic conditions, including dyslipidaemia, hypertension and CVD, all components of the metabolic syndrome^(2,3). Tea, from *Camellia sinensis*, exists in three basic forms: fermented black tea; semi-fermented oolong tea; non-fermented green tea⁽⁴⁾. Due to inactivation of polyphenol oxidase, green tea is rich (up to 30 % of the dry leaf weight) in flavanols known as catechins⁽⁵⁾. Catechins have been reported to have many biological effects, including anti-mutation⁽⁶⁾, anti-carcinogenesis⁽⁷⁾, anti-oxidation⁽⁸⁾ and anti-angiogenesis⁽⁹⁾ properties.

Research into the relationship between green tea and obesity-related insulin resistance syndrome has shown that green tea enhances *in vitro* insulin activity⁽¹⁰⁾, enhances insulin sensitivity in human subjects⁽¹¹⁾ and rat⁽¹²⁾, and reduces hypertriacylglycerolaemia in mice⁽¹³⁾. The main active component in green tea mediating these effects seems to be epigallocatechin gallate (EGCG)^(14,15).

Mechanisms explaining the effects of green tea and its components on obesity-related metabolic disturbances are not fully understood and some findings are contradictory. For example, one study reported that green tea decreased the translocation of the insulin-dependent GLUT4 in adipose tissue⁽¹⁶⁾ while another⁽¹⁷⁾ found an increasing effect of green tea on GLUT4 content of adipocytes. There are also conflicting findings on the relationship between green tea polyphenols and the important transcription factors involved in lipid and glucose homeostasis (PPAR $\alpha^{(18,19)}$ and PPAR $\gamma^{(16,20)}$). Furthermore, many studies used high concentrations of catechins that may not reflect typical consumption.

Our laboratory has demonstrated that obesity in the dog produces a metabolic disorder nearly identical to that seen in the obese human subject^(21,22). Moreover, the dog genome has been sequenced⁽²³⁾ supporting use of the obese dog as a model to study human metabolic disorders and link these changes to molecular studies.

The purpose of the present study in dogs was to examine the effects of extended nutritional supplementation with green tea on insulin sensitivity and plasma lipid concentrations and to determine whether transcriptional changes occur in liver, skeletal muscle and/or visceral and subcutaneous adipose tissue. We measured the expression of PPAR α and PPAR γ in their specific tissues and the expression of target genes including lipoprotein lipase (LPL), adiponectin and GLUT4; LPL expression is mediated by both PPAR α and PPAR γ whereas adiponectin and GLUT4 expression is mediated only by PPAR γ^{24} .

Abbreviations: EGCG, epigallocatechin gallate; HOMA-IR, homeostasis model of insulin resistance; LPL, lipoprotein lipase; TC, total cholesterol. * Corresponding author: Patrick Nguyen, fax +33 240 687746, email pnguyen@vet-nantes.fr

Materials and methods

Animals and diet

The ten obese and insulin-resistant beagle dogs (neutered females) were all healthy adults (mean age 4 years) with a mean body weight of 14.2 (SEM 0.4)kg (ideal body weight 10.1 (SEM 0.2)kg). All had a body condition score of 7 or 8 on the 9-point scale⁽²⁵⁾. They were housed at the National Veterinary School of Nantes according to the regulations for animal welfare of the French Ministry of Agriculture and Fisheries. The experimental protocol adhered to European Union guidelines and was approved by the local Animal Use and Care Advisory Committee.

Before the study for a period of 6 months, the dogs were fed a single hyperenergetic meal each day comprising 28 g/kg of a dry commercially available and nutritionally complete diet (18 MJ metabolisable energy/kg, 32 % protein, 20 % fat) to induce obesity. The dogs continued to receive these rations throughout the 12-week study.

Obese and insulin-resistant dogs were randomly divided into two groups: a green tea group $(n \ 6)$, a control group $(n \ 4)$. For 12 weeks, the green tea group received a capsule of green tea extract (80 mg/kg per d: a nutritionally relevant, non-pharmacological dose) orally just before the daily meal, whilst the control group received an empty capsule. The freeze-dried green tea extract (Vitamin Shoppe, North Bergen, NJ, USA) contained: epicatechin 35.7 mg/g; epicatechin gallate 64.8 mg/g; epigallocatechin 20.2 mg/g; EGCG 153.1 mg/g. Body weight and food intake were monitored twice weekly.

Body composition

Body composition was determined using isotopic dilution before and after 12 weeks' supplementation. D₂O (99.9% D/H; Euriso-top, Gif-sur-Yvette, France) was injected subcutaneously following a 24 h fast, with jugular vein blood samples (into heparin) collected 5 h later. The whole blood was centrifuged (4°C, 2124g for 10 min) and plasma deuterium concentration assessed (using Fourier transform IR spectroscopy; Brüker SA, Wissembourg, France).

Lipid profile

Jugular vein blood samples were collected once weekly (into EDTA) following a 24 h fast, for measurement of plasma TAG, total cholesterol (TC) and NEFA concentrations. Blood was immediately centrifuged (at 4° C, 2124g for 10 min) and stored (at -80° C) until further analysis.

Fast protein liquid chromatography analysis for lipoprotein separation was performed at room temperature using two P-500 pumps (1 Mpa), a MV-7 place multi-injection with a 200 μ l loop, two Superose 6HR 10/30 columns in quick succession, a UV monitor UV-1, a FRAC-100 fraction collector and a LCC-501 Plus controller. The absorbance of the eluent was monitored continuously at 280 nm using a UV monitor. The system was controlled by FPLC DIRECTOR software (Amersham Pharmacia Biotech Inc., Orsay, France). Elution was performed in a 1 mM-EDTA, 154 mM-NaCl and 0.02 % NaN₃ (pH 8.2) buffer. The buffer was filtered through a 0.22 μ m filter (Membrane filters type GV; Duropore®,

Millipore). The column was washed with an aqueous ethanol solution (20%). Plasma (200 μ l) was injected and elution was performed at a flow of 0.35 ml/min. The fractions were collected from 35 to 110 min and the columns were washed for 40 min at the end of each run. Fast protein liquid chromatography was programmed to collect elution volume from 10 ml to 40 ml, which represented seventy-five fractions of 350 μ l and resolved three lipoprotein fractions: VLDL (fractions 3 to 11, elution volume 12.95 to 15.75 ml), to LDL (fractions 15 to 39, elution volume 17.15 to 25.55 ml), to HDL1 (fractions 40 to 61, elution volume 26.90 to 33.25 ml). These fractions were subsequently analysed for TAG and TC as described later.

Euglycaemic-hyperinsulinaemic clamp

In vivo insulin sensitivity was determined using a 3h euglycaemic-hyperinsulinaemic clamp, performed following a 24 h fast both before and after 12 weeks' supplementation, as previously described⁽²¹⁾. Briefly, hyperinsulinaemia was induced by infusing human insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) via a catheter placed into the cephalic vein (4 mU/kg for 1 min and 2 mU/kg per min for the duration of the experiment). Glucose (Glucose 20%; Laboratoire Aguettant, Lyon, France) was clamped at basal level by adjustment of the glucose infusion rate in the cephalic vein. Blood samples were drawn from a jugular catheter every 5 min from 0 to 60 min and every 10 min from 60 to 180 min. These samples were placed in ice-cold heparinized tubes and centrifuged (at 4°C, 2124g for 10 min) and stored (at -80°C) until insulin analysis. Insulin sensitivity index was defined as the mean glucose infusion rate (mg/kg per min) divided by the mean plasma insulin (μ U/ml) of the last $60 \min$ of the clamp⁽²⁶⁾.

Homeostasis model assessment of insulin resistance index

Homeostasis model assessment of insulin resistance (HOMA-IR) yields a formula for insulin resistance and derives from fasting insulin (I₀ (mIU/l)) and glucose (G₀ (mmol/l)) concentrations. This index is defined by:

HOMA-IR =
$$G_0 \times I_0 / 22.5$$
.

Chemical analysis

Rapid determination of blood glucose during clamping was achieved using the glucose oxidase method (Glucotrend® Plus; Roche Diagnostics, Mannheim, Germany). Plasma insulin concentrations were measured using a commercial RIA kit (RIA Insik-5; Diasorin, Saluggia, Italy). TAG, TC and NEFA were analysed in plasma using enzymatic methods (Triglycérides enzymatiques PAP 150; BioMérieux, Marcy-l'Etoile, France, Cholesterol RTU; Biomérieux, Marcy-l'Etoile, France and NEFA C; WAKO, Oxoid, Dardilly, France).

RNA extraction

Visceral and subcutaneous adipose tissue and skeletal muscle and liver biopsies were obtained intraoperatively under anaesthesia, following a 24 h fast both before and after 12 weeks'

1209

supplementation. Skeletal muscle biopsies were removed from the tibialis anterior. Approximately 100 mg each tissue was cleaned in saline. TRIzol reagent (1 ml; Gibco BRL, Grand Island, NY, USA) was added and the tissue immediately frozen in liquid N. RNA was extracted from frozen tissues using TRIzol reagent according to the manufacturer's instructions. Total RNA concentration was quantified by spectrophotometric absorbance at 260 nm.

Reverse transcription and real-time PCR analysis

Total RNA (1 μ g) was reverse-transcribed in a 20 μ l reaction volume using random primers (Pharmacia, Saclay, Orsay Cedex, France) and Superscript II Moloney leukaemia virus RT (according to the manufacture's instructions; Life Technologies, Cergy Pontoise, France).

Quantitative real-time PCR was conducted with a rotorgene 2000 (Ozyme, Saint-Quentin en Yvelines, France) in a 20 µl mixture containing 1X SYBR Green (Roche Diagnostic, Meylan, France), 0.25 mM-dNTP, each primer (0.5 mM), 2 U Taq Titanium DNA polymerase (Ozyme) and 2 µl cDNA mixture of each sample. Glyceraldehyde-3-phosphate dehydrogenase was used as a reference for initial RNA loading. The sense/antisense primers (Genosys, Pampisford, UK) were designed using GeneJokey Software (Biosoft, Ferguson, MO, USA). The specificity of PCR primers and the annealing temperature were tested under normal PCR conditions with temperature gradient (55°C to 70°C) as annealing (Table 1). The real-time PCR conditions were 95°C for 300 s (to activate the hot start enzyme) followed by: (1) thirty-five cycles of 95°C for 5 s, 63°C for 10 s, 72°C for 10 s and 83°C for 15 s for PPAR γ ; (2) thirty-five cycles of 95°C for 5 s, 62°C for 15 s, 72°C for 15 s and 82°C for 15 s for PPARα; (3) forty cycles of 95°C for 5 s, 62°C for 15 s, 72°C for 15 s and 86°C for 15 s for the LPL; (4) forty-five cycles of 95°C for 5 s, 70°C for 15 s, 72°C for 15 s and 85°C for 15 s for GLUT4; (5) forty cycles of 95°C for 5 s, 69°C for 15 s, 72°C for 15 s and 86°C for 15 s for adiponectin; (6) thirty cycles of 95°C for 5 s, 69°C for 15 s, 72°C for 15 s and 86°C for 15 s for the glyceraldehyde-3-phosphate dehydrogenase. The fluorescence cycle threshold (Ct) was calculated to quantify the relative amount

Table 1. Sense/antisense primers used for glyceraldehyde-3-phosphate deshydrogenase (GAPDH), PPAR α , PPAR γ , adiponectin, lipoprotein lipase (LPL) and GLUT4 relative quantification and annealing temperatures determined for each PCR primer*

Gene	Primers sense/antisense	Annealing T°C
GAPDH	5'-ACAGTCAAGGCTGAGAACGG-3'	69°C
	5'-CCACAACATACTCAGCACCAGC-3'	
PPARα	5'-TTATCACAGACACGCTCTCACC-3'	62°C
	5'-GTGGACTCCGTAATGGTAGC-3'	
PPARγ	5'-CATTTACACGATGCTGGCGTCC-3'	63°C
·	5'-CTCCACTGAGAATAATGACGGC-3'	
Adiponectin	5'-CCAGGTCTTGTTGGTCCTAAGG-3'	69°C
·	5'-ACACTGAATGCCGAACGG-3'	
LPL	5'- GAAGAAAATCCAAGTAAGGC-3'	62°C
	5'-ACATTTTGCTCGGTCTTTTGGC-3'	
GLUT4	5'-GACAAGCAACTTCATCATTGGC-3'	70°C
	5'-AGGAAGGTGAAGATGAAGAAGG-3'	

* For details of procedures, see Materials and methods.

of gene expression. Results are expressed according to the $2^{-\Delta\Delta Ct}$ method⁽²⁷⁾. The level of expression before green tea supplementation was arbitrarily set at 100 %.

Statistical analysis

Data are expressed as means with their standard errors of the mean. The statistical analysis used Stat View 5.0 software (SAS Institute, Cary, NC, USA). Comparison among means was performed by Student's t test for paired values. A *P* value < 0.05 was considered to be significant.

Results

Body weight, food intake and body composition

There was no significant difference from baseline in either group in terms of body weight or food intake at any time point. The mean values of the food intake during the 12 weeks of treatment was 578 (SEM 29) kJ/kg⁰⁷⁵ in the green tea group and 578 (SEM 25) kJ/kg⁰⁷⁵ in the control group. At 12 weeks (after treatment), there was no difference from baseline (week 0, before treatment) in body fat mass in either group (Table 2).

Insulin sensitivity

The euglycaemic-hyperinsulinaemic clamp data (fasting glucose and insulin, plateau of insulin level, glucose infusion rate and insulin sensitivity index) in normal-weight and obese dogs before and after treatment in the green tea group and in the control group are shown in Table 3.

Basal glycaemia did not significantly change when dogs became obese in either group (green tea and control). Also, basal glycaemia did not significantly change after treatment compared with baseline (before treatment) in either group. Basal insulinaemia tended to increase when dogs became obese and to decrease after green tea treatment but these changes were not significant. During the clamps, plateau of insulin level increased when the dogs became obese in both groups and tended to decrease after green tea treatment. Glucose infusion rate needed to maintain euglycaemia under hyperinsulinaemic conditions was lower in obese dogs than in normal dogs $(P \le 0.001)$ in either group and was elevated after green tea treatment (P < 0.05). Consequently, insulin sensitivity index was markedly decreased when dogs became obese (-59)(SEM 12) % in the green tea group and -73 (SEM 15) % in the control group compared with normal weight state, P < 0.001). Insulin sensitivity index was markedly increased by green tea supplementation (by 60 (SEM 11)% compared with baseline (before treatment; P < 0.01), whereas no change was observed in the control group.

HOMA-IR index tended to increase when the dogs became obese (3.58 (SEM 0.73) v. 4.68 (SEM 0.76) in the green tea group and 3.35 (SEM 0.81) v. 4.14 (SEM 1.03) in the control group) and to decrease after green tea treatment (4.68 (SEM 0.76) v. 3.75 (SEM 0.55)). However these changes are not significant.

Plasma lipid concentration

Lipid parameter data are summarized in Table 4.

Table 2. Body weight and body composition of the 12 weeks' green tea-supplemented and control obese dogs*

(Values are presented as means with their standard errors)

		Green t	tea (<i>n</i> 4)			Control (n 6)						
	Wee	ek 0	Wee	k 12	Wee	ek 0	Wee	k 12				
	Mean SEM		Mean	SEM	Mean	SEM	Mean	SEM				
Body weight (kg) Body fat mass (kg)	13·62 5·80	0∙55 0∙48	13∙86 5∙20	0∙67 0∙61	14∙91 6∙01	0∙52 0∙40	15·05 5·76	0∙68 0∙28				

There was no significant difference between week 0 (before treatment) and week 12 (after treatment) of the protocol in either group.

* For details of animals and procedures, see Materials and methods

Diet-induced obesity increased plasma TAG and NEFA by respectively 71 (SEM 19)% (P < 0.001) and 44 (SEM 10)% (P < 0.05) in the green tea group and by 95 (SEM 23)% (P < 0.05) and 43 (SEM 15)% (P < 0.05) in the control group. TC concentrations did not change when dogs became obese in either group.

Plasma TAG (-48 (SEM 8)% compared with baseline (before treatment; P < 0.01) and VLDL-TAG were reduced by green tea supplementation, whereas no change was observed in the control group. There was no significant difference from baseline (before treatment) in plasma NEFA, TC, LDL-cholesterol and HDL-cholesterol concentrations in either group. However, plasma NEFA tended to decrease after green tea treatment, whereas plasma NEFA tended to increase in the control group.

mRNA expression of PPAR γ , lipoprotein lipase, adiponectin and GLUT4 in visceral and subcutaneous adipose tissue

The expression of the reference gene did not significantly change in visceral and subcutaneous adipose tissue between the beginning (week 0) and the end (week 12) of the treatment (data not shown).

Compared with baseline, expression of PPAR γ , LPL, adiponectin and GLUT4 mRNA in visceral adipose tissue (*n* 6) was dramatically elevated after 12 weeks of green tea supplementation. Expression was approximately 2-fold greater for PPAR γ (*P*<0.05) and LPL (*P*<0.05) and 4-fold greater for adiponectin (*P*<0.05) and GLUT4 (*P*<0.05), whereas no change was seen in the expression of any of these genes in the control group (*n* 4) (Fig. 1). Interestingly, in the subcutaneous adipose tissue of green tea-supplemented dogs (*n* 6), PPAR γ , LPL, adiponectin and GLUT4 mRNA expression was increased by a similarly great extent (3-fold, 10-fold, 6-fold and 3-fold, respectively, *P*<0.05; Fig. 2) compared with baseline.

mRNA expression of PPAR α and lipoprotein lipase in liver

The expression of the reference gene did not significantly change in liver between the beginning (week 0) and the end (week 12) of the treatment (data not shown).

In liver, the mRNA expression of PPAR α , and its target gene, LPL, remained unchanged in both groups (Fig. 3).

mRNA expression of PPAR α , lipoprotein lipase and GLUT4 in skeletal muscle

The expression of the reference gene did not significantly change in skeletal muscle tissue between the beginning (week 0) and the end (week 12) of the treatment (data not shown).

In skeletal muscle, green tea supplementation markedly increased the expression of PPAR α (by 100 (SEM 18)%, P < 0.01) and LPL (by 270 (SEM 43)%, P < 0.01), but not GLUT4, compared with baseline (Fig. 4).

Discussion

In the present study, we have shown that 12 weeks' green tea supplementation in obese insulin-resistant dogs increases insulin sensitivity, decreases plasma TAG concentrations and increases expression of PPAR α , PPAR γ and their target genes LPL, GLUT4 and adiponectin. Body weight and fat mass were not affected.

Many previous human studies used high concentrations of catechins^(20,28) that may not reflect typical consumption. A 2.5 % (w/v) tea concentration in 227 ml water represents the typical strength of brews consumed by human individuals and may contain approximately 340 mg catechins⁽²⁹⁾. Thus, based on metabolic body weight (BW^{0.75}), the consumption of green tea catechins by the dogs in the current study was nutritionally relevant and non-pharmacological, being equivalent to three cups of tea in human individuals. Dogs readily absorb EGCG (approximately 20% of the dose) after oral administration⁽³⁰⁾; it is then distributed widely to a variety of epithelial tissues.

Very few studies have been reported regarding the *in vivo* effects of green tea or its catechins on insulin sensitivity^(11,20,31). Moreover, these studies used glucose tolerance tests rather than the gold standard for assessing insulin sensitivity⁽³²⁾. In the present study, euglycaemic hyperinsulinaemic clamps showed a strong effect of green tea extract in improving insulin sensitivity in obese, insulin-resistant dogs. Fasting insulin concentrations have tended to increase when the dogs became obese and to decrease after green tea treatment. However, basal insulin and glucose concentrations did not significantly change. We have compared our clamp results with the data of HOMA-IR index, a simpler method to measure insulin sensitivity usually used in clinical

Nutrition
ð
Journal
British
N

able 3. Fasting insulin and glucose concentrations, plateau of insulin level, glucose infusion rate (Ginf) and insulin sensitivity index (I_{is}) during the clamp in green tea group and control group at the normal weight state and at the obese state before and after treatment‡

(Values are presented as means with their standard errors)

			Green tea g	roup (<i>n</i> 6)					Control gro	up (<i>n</i> 4)		
	Normal	weight	Before treat	ment	After treatm	ent	Normal	weight	Before trea	tment	After treat	nent
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
Basal glycaemia (g/l)	0.88	0.02	0.88	0.03	0.91	0.04	0.90	0.05	0.89	0.03	0.82	0.03
Basal insulinaemia (µU/ml)	16.2	2.9	21.5	9.0 Ю	16.7	2.4	14.8	0.0 Ю	18-5	3·9	20.5	0.0 0
Plateau of insulin level (μU/ml)	148.7	18-2	184.5	12·8	134.8	8.0	122.1	18·8	183.0†	19.8	189.3†	5.0
Ginf (mg/kg per min)	22·0	0.8	11.7†††	1 Ó	13.6*†††	.	25.5	4.1	13.6111	2.6	11.5+++	1.6
l _{is} (mg.ml/kg per μU per min)	0.158	0.016	0.065111	0.007	0.102**†††	0.009	0.221	0.038	0.060111	0.010	0.060111	0.013
*P<0.05; **P<0.01 v. before treatmen †P<0.05; †††P<0.001 v. nomal weigl	lt. ht state.											

t For details of animals and procedures, see Materials and methods

and epidemiological studies when only fasting insulin and glucose values are available. We have found that HOMA-IR index tended to increase when the dogs became obese and to decrease after green tea treatment. The changes did not reach the statistical significance level probably due to the small sample size.

To understand the mechanisms that could explain these effects of green tea on insulin sensitivity, we examined the expression of proteins involved in glucose metabolism in visceral and subcutaneous adipose tissue and skeletal muscle. We showed that GLUT4 was markedly increased in visceral and subcutaneous adipose tissues, but not in skeletal muscle, after 12 weeks of green tea supplementation. The insulindependent GLUT4, located in muscle cells and adipocytes, increases the utilization of glucose by these tissues⁽³³⁾. Abel and colleagues presented convincing evidence that insulin resistance was initiated in adipose tissue and that adipose tissue may play a pivotal role in the induction of insulin resistance in muscle and liver⁽³⁴⁾. This would explain why, in the present study, green tea increased GLUT4 expression in adipose tissue but not in skeletal muscle. We have not examined the translocation of GLUT4 from intracellular storage sites to the plasma membrane. Thus, it is possible that green tea increases GLUT4 translocation and not GLUT4 expression in muscle cells.

The current results also showed that green tea increases adiponectin expression in both types of adipose tissue. Adiponectin is strongly inversely correlated to insulin resistance and improves insulin sensitivity by repressing gluconeogenesis and favouring glucose and NEFA oxidation by muscle⁽³⁵⁾.

Other mechanisms could explain the effects of green tea catechins on obesity-related insulin resistance. EGCG increases tyrosine phosphorylation of the insulin receptor and insulin receptor substrate $1^{(15)}$. It has also been suggested that tea catechins could lower glucose absorption in the intestinal tract by inhibiting its specific transporters⁽³⁶⁾.

There have been several epidemiological and clinical investigations of the effects of green tea on plasma lipids in human subjects^(31,37,38), with contradictory findings. In rodents, Sayama and co-workers⁽¹³⁾ found a TAG-lowering effect of green tea and no change in plasma TC concentrations, whereas Ashida and colleagues⁽¹⁶⁾ reported that green tea supplementation decreased TC, LDL-cholesterol, HDL-cholesterol and NEFA levels with no change in TAG concentrations. The present study found a marked decrease in plasma TAG concentrations in the green tea group related to a decrease in VLDL-TAG. However, no difference was observed in the cholesterol profile or NEFA levels.

LPL is an enzyme that hydrolyses circulating TAG-rich lipoproteins⁽³⁹⁾. To explain the hypertriacylglycerolaemic effect of green tea, we measured LPL mRNA expression. Our results showed for the first time that LPL expression was dramatically elevated in visceral and subcutaneous adipose tissues, and in skeletal muscle, by green tea supplementation. It has been shown that EGCG is a potent inhibitor of apoB100 secretion⁽⁴⁰⁾, possibly through microsomal transfer protein inhibition, as demonstrated *in vitro* for other flavonoids⁽⁴¹⁾. Furthermore, EGCG promotes the accumulation of TAG in cytosolic lipid droplets, thereby diverting lipids from the assembly of VLDL to storage in the cytosol⁽⁴²⁾. *In vivo* measurement of the processes involved in VLDL

Table 4. Fasting plasma TAG, total cholesterol (TC), NEFA, VLDL-TAG, LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) in green tea group and control group at the normal weight state and at the obese state before and after treatment[‡]

(Values are presented as means with their standard errors)

			Green tea	areen tea group (n 6)				Control group (n 4)						
	Normal weight		Before tre	eatment	After treatment		Normal weight		Before treatment		After treatment			
_	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM		
TAG (mmol/l)	0.69	0.05	1.16†††	0.10	0.58**	0.06	0.55	0.02	1.05†	0.10	0.98†	0.17		
TC (mmol/l)	6.35	0.42	6.24	0.48	6.85	0.21	6.07	0.76	6.97	1.12	6.79	0.63		
NEFA (mmol/l)	0.70	0.07	0.98†	0.08	0.86	0.08	0.56	0.13	0.88†	0.13	1.13†	0.20		
VLDL-TG (mmol/l)	NA		0.537	0.093	0.273**	0.042	N	Ą	0.385	0.032	0.453	0.067		
LDL-C (mmol/l)	N	A	0.881	0.169	0.999	0.173	N	Ą	1.016	0.243	0.916	0.142		
HDL-C (mmol/ĺ)	N	A	5.374	0.403	5.448	0.388	NA		5.377	0.860	5.381	0.753		

NA, not available.

**P < 0.01 v. before treatment.

+P<0.05; +++P<0.001 v. normal weight state

‡ For details of animals and procedures, see Materials and methods.

metabolism, particularly apoB100 and LPL activity, would be required to explain the hypotriacylglycerolaemic effects of green tea.

PPAR are transcription factors for the genes involved in glucose and lipid homeostasis, including LPL, adiponectin and GLUT4. Three isotypes of PPAR have been identified (α , γ , β/δ). The amino acid sequence of the ligand binding domain of PPAR α in the dog was found to be 97% identical to that of man. PPAR α is predominantly expressed in tissues with a high rate of fat catabolism (e.g. liver and muscle). The expression of PPAR γ is high in adipose tissue, where it triggers adipocyte differentiation and induces the expression of genes critical for adipogenesis (for review see⁽²⁴⁾). We have shown that green tea increases PPAR α expression in skeletal muscle (but not in liver) and increases PPAR γ expression in visceral and subcutaneous adipose tissues.

Tea catechins activated PPARα in cell culture⁽¹⁹⁾ and increased PPARα and PPARγ expression in hamster liver⁽²⁰⁾. The use of fenofibrate⁽⁴³⁾ and other PPARα activators⁽⁴⁴⁾ showed that the induction of PPARα mRNA might be a property shared by all members of this class of chemical. Moreover, Davies *et al.*⁽⁴⁵⁾ showed that the ability of troglitazone, a thiazolidinedione, to up regulate PPARγ could be due to its antioxidant properties. Green tea catechins are potent antioxidants⁽⁸⁾ and, thus, could act similarly. Antioxidants (via intracellular redox state) could regulate the transcription factors, NF-κB and activator protein-1⁽⁴⁶⁾, and PPARγ could







Fig. 2. Relative expression of (a) PPAR γ , (b) lipoprotein lipase (LPL), (c) GLUT4 and (d) adiponectin mRNA in subcutaneous adipose tissue of 12 weeks' green tea-supplemented (\blacksquare ; *n* 6) and control (\Box ; *n* 4) obese dogs. Values are presented as means with their standard errors. **P*<0.05 *v*. baseline (week 0). For details of animals and procedures, see Materials and methods.

be regulated by these transcription factors⁽⁴⁷⁾. Given the increase in the expression of PPAR α and PPAR γ and their target genes in their specific tissues, we hypothesize that tea catechins might represent new PPAR activators.

1214

VS British Journal of Nutrition



Fig. 3. Relative expression of (a) PPAR α and (b) lipoprotein lipase (LPL) mRNA in the liver of 12 weeks' green tea-supplemented (\blacksquare ; *n* 6) and control (\Box ; *n* 4) obese dogs. Values are presented as means with their standard errors. For details of animals and procedures, see Materials and methods.

Clinical studies have shown that body weight and fat mass of human subjects and animals given green tea catechins decreased significantly^(28,48). In the present study, body weight and body composition were not affected by green tea supplementation. During treatment, our dogs were fed approximately according to the National Research Council recommendation for maintenance, which could explain why body weight remains stable in the green tea and control groups. An elevation of the expression of PPARy, LPL and GLUT4 in adipose tissue, without any effect on plasma NEFA concentration, would enhance fat depots - similar to thiazolidinedione⁽⁴⁹⁾. An increase in uncoupling protein activity in adipose tissue might regulate the energy balance by uncoupling mitochondrial respiration - as has been shown with thiazolidinedione⁽⁵⁰⁾. Some reports suggested that green tea catechins not only promote energy expenditure but also stimulate the oxidation of lipids by the known inhibitory effect of catechins and notably EGCG on catechol-Omethyltransferase, an enzyme that degrades noradrenaline⁽⁵¹⁾. Taken together, we can hypothesize that green tea catechins enhance lipid catabolism, which could counteract the PPARy agonist-induced lipogenesis. This could explain the absence of change in body composition after green tea treatment. Green tea catechins could trigger a shift of fat distribution from visceral to subcutaneous adipose depots as has been shown with a PPAR γ agonist, the pioglitazone⁽⁵²⁾. It is well known that visceral adipocytes are lipolytically more active than subcutaneous fat cells and removal of visceral fat enhances insulin sensitivity⁽³⁴⁾.

In conclusion, the present results demonstrate that extended nutritional supplementation with green tea may reverse obesity-related metabolic disturbances by improving insulin sensitivity and decreasing VLDL-TAG concentrations. We also



Fig. 4. Relative expression of (a) PPAR α , (b) lipoprotein lipase (LPL) and (c) GLUT4 mRNA in skeletal muscle of 12 weeks' green tea-supplemented (**■**; *n* 6) and control (\Box ; *n* 4) obese dogs. Values are presented as means with their standard errors. ***P*<0.01 *v*. baseline (week 0). For details of animals and procedures, see Materials and methods.

observed an increase in the expression of PPAR α and PPAR γ , important transcription factors involved in lipid and glucose homeostasis. The mRNA expression of their target genes (LPL, adiponectin and GLUT4) was increased and could explain the beneficial effects of green tea in obese, insulinresistant dogs. According to previous studies^(19,20), these results suggest that green tea (or its catechins) may be new natural PPAR activators. The obese, insulin-resistant dog model can thus be used, in further studies, to assess the *in vivo* effects of EGCG, which is the principal – and probably the most active – catechin in green tea.

Acknowledgements

The authors are grateful to Samuel Ninet, Gérald Pondevie and Philippe Bleis for taking care of the animals and for technical assistance. None of the authors has financial or personal conflicts of interest with regard to this study.

References

- Zimmet P, Alberti KG & Shaw J (2001) Global and societal implications of the diabetes epidemic. *Nature* 414, 782–787.
- Alberti KG & Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15, 539–553.
- Zavaroni I, Bonini L, Fantuzzi M, Dall'Aglio E, Passeri M & Reaven GM (1994) Hyperinsulinaemia, obesity, and syndrome X. J Intern Med 235, 51–56.
- Cheng TO (2006) All teas are not created equal: the Chinese green tea and cardiovascular health. *Int J Cardiol* 108, 301–308.
- Graham HN (1992) Green tea composition, consumption, and polyphenol chemistry. *Prev Med* 21, 334–350.
- Okuda T, Mori K & Hayatsu H (1984) Inhibitory effect of tannins on direct-acting mutagens. *Chem Pharm Bull (Tokyo)* 32, 3755-3758.
- Yang CS & Wang ZY (1993) Tea and cancer. J Natl Cancer Inst 85, 1038–1049.
- Sung H, Nah J, Chun S, Park H, Yang SE & Min WK (2000) In vivo antioxidant effect of green tea. *Eur J Clin Nutr* 54, 527–529.
- 9. Cao Y & Cao R (1999) Angiogenesis inhibited by drinking tea. *Nature* **398**, 381.
- Anderson RA & Polansky MM (2002) Tea enhances insulin activity. J Agric Food Chem 50, 7182–7186.
- Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T & Kimura I (2004) Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. *BMC Pharmacol* 4, 18.
- Wu LY, Juan CC, Ho LT, Hsu YP & Hwang LS (2004) Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. J Agric Food Chem 52, 643–648.
- Sayama K, Lin S, Zheng G & Oguni I (2000) Effects of green tea on growth, food utilization and lipid metabolism in mice. *In Vivo* 14, 481–484.
- Kao YH, Hiipakka RA & Liao S (2000) Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. *Endocrinology* 141, 980–987.
- Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M & Granner DK (2002) Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. *J Biol Chem* 277, 34933–34940.
- Ashida H, Furuyashiki T, Nagayasu H, Bessho H, Sakakibara H, Hashimoto T & Kanazawa K (2004) Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. *Biofactors* 22, 135–140.
- Wu LY, Juan CC, Hwang LS, Hsu YP, Ho PH & Ho LT (2004) Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. *Eur J Nutr* 43, 116–124.
- Jiao HL, Ye P & Zhao BL (2003) Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate. *Free Radic Biol Med* 35, 1121–1128.
- Lee K (2004) Transactivation of peroxisome proliferator-activated receptor alpha by green tea extracts. J Vet Sci 5, 325–330.
- Li RW, Douglas TD, Maiyoh GK, Adeli K & Theriault AG (2006) Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model. *J Ethnopharmacol* 104, 24–31.
- Bailhache E, Ouguerram K, Gayet C, Krempf M, Siliart B, Magot T & Nguyen P (2003) An insulin-resistant hypertriglyceridaemic normotensive obese dog model: assessment of insulin resistance by the euglycaemic hyperinsulinaemic clamp in

1215

S. Serisier et al.

combination with the stable isotope technique. J Anim Physiol Anim Nutr (Berl) 87, 86–95.

- Bailhache E, Nguyen P, Krempf M, Siliart B, Magot T & Ouguerram K (2003) Lipoproteins abnormalities in obese insulin-resistant dogs. *Metabolism* 52, 559–564.
- Kirkness EF, Bafna V, Halpern AL, *et al.* (2003) The dog genome: survey sequencing and comparative analysis. *Science* 301, 1898–1903.
- Desvergne B & Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr Rev* 20, 649–688.
- Laflamme DP (2005) Nutrition for aging cats and dogs and the importance of body condition. *Vet Clin North Am Small Anim Pract* 35, 713–742.
- Beard JC, Bergman RN, Ward WK & Porte D Jr (1986) The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. *Diabetes* 35, 362–369.
- Livak KJ & Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25, 402–408.
- Klaus S, Pultz S, Thone-Reineke C & Wolfram S (2005) Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. *Int J Obes (Lond)* 29, 615–623.
- Bu-Abbas A, Dobrota M, Copeland E, Clifford MN, Walker R & Ioannides C (1999) Proliferation of hepatic peroxisomes in rats following the intake of green or black tea. *Toxicol Lett* 109, 69–76.
- Swezey RR, Aldridge DE, LeValley SE, Crowell JA, Hara Y & Green CE (2003) Absorption, tissue distribution and elimination of 4-[(3)h]-epigallocatechin gallate in beagle dogs. *Int J Toxicol* 22, 187–193.
- Ryu OH, Lee J, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS & Choi KM (2006) Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. *Diabetes Res Clin Pract* 71, 356–358.
- Radziuk J (2000) Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 85, 4426–4433.
- 33. Park SY, Choi GH, Choi HI, Ryu J, Jung CY & Lee W (2005) Calorie restriction improves whole-body glucose disposal and insulin resistance in association with the increased adipocytespecific GLUT4 expression in Otsuka Long-Evans Tokushima fatty rats. Arch Biochem Biophys 436, 276–284.
- Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI & Kahn BB (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. *Nature* 409, 729–733.
- Mlinar B, Marc J, Janez A & Pfeifer M (2007) Molecular mechanisms of insulin resistance and associated diseases. *Clin Chim Acta* 375, 20–35.
- 36. Kobayashi Y, Suzuki M, Satsu H, Arai S, Hara Y, Suzuki K, Miyamoto Y & Shimizu M (2000) Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem 48, 5618–5623.
- Kono S, Shinchi K, Wakabayashi K, Honjo S, Todoroki I, Sakurai Y, Imanishi K, Nishikawa H, Ogawa S & Katsurada

M (1996) Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. *J Epidemiol* **6**, 128–133.

- Tokunaga S, White IR, Frost C, Tanaka K, Kono S, Tokudome S, Akamatsu T, Moriyama T & Zakouji H (2002) Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. *Ann Epidemiol* 12, 157–165.
- Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B & Auwerx J (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response *via* a PPRE in the lipoprotein lipase gene. *EMBO J* 15, 5336–5348.
- Yee WL, Wang Q, Agdinaoay T, Dang K, Chang H, Grandinetti A, Franke AA & Theriault A (2002) Green tea catechins decrease apolipoprotein B-100 secretion from HepG2 cells. *Mol Cell Biochem* 229, 85–92.
- 41. Allister EM, Borradaile NM, Edwards JY & Huff MW (2005) Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. *Diabetes* 54, 1676–1683.
- 42. Li L, Stillemark-Billton P, Beck C, *et al.* (2006) Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL. *J Lipid Res* **47**, 67–77.
- Gebel T, Arand M & Oesch F (1992) Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. *FEBS Lett* **309**, 37–40.
- Sterchele PF, Sun H, Peterson RE & Vanden Heuvel JP (1996) Regulation of peroxisome proliferator-activated receptor-alpha mRNA in rat liver. *Arch Biochem Biophys* 326, 281–289.
- 45. Davies GF, McFie PJ, Khandelwal RL & Roesler WJ (2002) Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. *J Pharmacol Exp Ther* **300**, 72–77.
- Sen CK & Packer L (1996) Antioxidant and redox regulation of gene transcription. FASEB J 10, 709–720.
- 47. Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO & Li S (2001) Inhibition of the transcription factors AP-1 and NFkappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. *Int Immunopharmacol* 1, 803–812.
- 48. Nagao T, Komine Y, Soga S, Meguro S, Hase T, Tanaka Y & Tokimitsu I (2005) Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. *Am J Clin Nutr* **81**, 122–129.
- Fonseca V (2003) Effect of thiazolidinediones on body weight in patients with diabetes mellitus. *Am J Med* 115, Suppl. 8A, 42S-48S.
- Cortright RN, Zheng D, Jones JP, Fluckey JD, DiCarlo SE, Grujic D, Lowell BB & Dohm GL (1999) Regulation of skeletal muscle UCP-2 and UCP-3 gene expression by exercise and denervation. *Am J Physiol* 276, E217–E221.
- Dulloo AG, Seydoux J, Girardier L, Chantre P & Vandermander J (2000) Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord* 24, 252–258.
- Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ & Defronzo RA (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. *J Clin Endocrinol Metab* 87, 2784–2791.